The Recall Desk
CriticalFDA (Drugs)·D-1613-2014·Announced 2014-10-08

Black Ant capsules recalled for undeclared sildenafil

Eugene Oregon, Inc. is recalling Black Ant capsules because FDA testing found undeclared sildenafil. The product was marketed without an approved NDA or ANDA.

What this means for you

Highest-severity recall. Risk of serious injury or death is documented or strongly suspected. Stop using the product now and follow the agency's instructions.

Our severity reasoning: The agency classification is FDA Class I, which mandates a severity score of 5 according to the rubric.

Plain-English summary

Eugene Oregon, Inc. is recalling 136 boxes of Black Ant, 2800 mg, four capsules per box. The product was manufactured by Qinghai Baojiantang Pharmaceutical Co., Ltd. and distributed to retailers in Maryland, Texas, Florida, Pennsylvania, Illinois, New Jersey, Indiana, Louisiana, Washington, Maine, and South Carolina.

The recall was initiated because FDA laboratory analyses determined that the capsules contain undeclared sildenafil. The product was marketed without an approved New Drug Application (NDA) or Abbreviated New Drug Application (ANDA).

Consumers who have purchased this product should stop using it and contact the recalling firm for further instructions.

The recalled product

Product
Black Ant, 2800 mg, four capsules per box, Manufacturer Qinghai Baojiantang Pharmaceutical Co., Ltd.
Affected units
136

Is your product affected?

Check your packaging against the codes below. If any of them match, the product is part of this recall.

Lot numbers (1)

  • All lots

Distribution

Distributed in 11 states:

Part of a larger recall action

This product is one of 3 recalled by Eugene Oregon, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.

See all 3 products in this recall →

Same manufacturer · Eugene Oregon, Inc.

See all →